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Triggering receptor expressed on myeloid cell-1 (TREM-1) signaling is expressed on
neutrophils and monocytes that is necessary for the successful antimicrobial response
and resolution of inflammation in the gut. In this study, we determined the effect of
an anti-TREM-1 agonistic antibody (α-TREM-1) on colitis and identify its underlying
mechanism of action. Administration of α-TREM-1 alleviated colitis in mice and resolved
dysbiosis, which required TLR4/Myd88 signaling. α-TREM-1 increased the production
of neutrophil extracellular traps and interleukin-22 by CD177+ neutrophils, which led to
pathogen clearance and protection of the intestinal barrier. TREM-1 activation using an
α-TREM-1 antibody protects against colitis by rebalancing the microbiota and protecting
the epithelium against the immune response as well as modulates the function of
neutrophils and macrophages. These results highlight the importance of the TREM-1
pathway in intestinal homeostasis and suggest that α-TREM-1 treatment may be an
effective therapeutic strategy for inflammatory bowel disease.
Keywords: CD177, inflammatory bowel disease, neutrophil, macrophage, triggering receptor expressed on
myeloid cell
INTRODUCTION
The gut is constantly exposed tomicrobes. Unresolved pathogen clearance due to aberrant immune
responses and compromised mucosal healing perpetuate inflammation and tissue injury in the gut.
One factor determining the balance between bacterial clearance and tissue damage is the timely
induction of anti-inflammatory and mucosal healing molecules. Inflammatory bowel diseases
(IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory
disorders related to dysregulated immune responses, genetic susceptibility, and environmental
factors (1, 2). Recent studies have shown the importance of aberrant innate immune responses
to microbes in IBD pathogenesis (3). Myeloid cells, such as neutrophils, monocytes/macrophages,
and dendritic cells, primarily mediate this innate response (4). Excessive inflammation due to
unresolved infection, however, leads to prolonged inflammation and tissue damage.
Triggering receptor expressed on myeloid cells-1 (TREM-1) is expressed mainly primarily
on myeloid cells, such as including neutrophils, monocytes, and tissue macrophages (5), and is
Seo et al. Anti-TREM-1 Inhibits Colitis
dramatically induced on neutrophils and monocytes in
response to microbes, playing a critical role in modulating
infection-induced inflammation (6). TREM-1 downstream
signaling is linked with the phosphorylated DNAX activation
protein 12 (DAP12), phosphatidylinositol-3 kinase (PI3K),
and extracellular-signal-regulated kinase (ERK) in order to
amplify Toll-like receptors (TLRs). TREM-1 amplifies TLR
signaling, an important link between microbial populations and
inflammation (6). Although the exact ligand for TREM-1 is
unknown, cross-linking with an agonist antibody (α-TREM-1)
induces TREM-1-dependent responses, including increased
cytokine production, bactericidal activity, and phagocytosis in
monocytes, and promotion of degranulation and antimicrobial
function in neutrophils (6). Modulation of the TREM-1 pathway
has been shown to alter outcomes in several animal models
of inflammation (7, 8). Moreover, in a preclinical trial of
anti-TREM-1 therapy, the secretion of several proinflammatory
cytokines was suppressed in the inflamed intestinal tissues of
IBD patients (9). However, it has also been reported that a
TREM-1-antagonizing peptide attenuates colitis in mice (10).
Thus, the exact role of TREM-1 in driving chronic inflammation
in IBD is poorly understood.
We aimed to determine the effect of α-TREM-1 on intestinal
inflammation and explored its underlying mechanism of
action. We showed that TREM-1 is indispensable for
the innate immune response and barrier function in
colitis. Furthermore, we showed that α-TREM-1 induced
CD177+ neutrophils and promoted wound healing
through interactions with macrophages and intestinal
epithelial cells (IEC).
MATERIALS AND METHODS
Colitis and Animal Models
TLR4-deficient BALB/c and Myd88-deficient C57BL/6 mice
were provided by the Korea Research Institute of Bioscience
and Biotechnology (Daejeon, South Korea). dextran sodium
sulfate (DSS) (MP Biomedicals, Solon, OH, USA) or 2,4,6-
trinitrobenzene sulfonic acid (TNBS) (Thermo Fisher Scientific,
Waltham, MA, USA) were used to induce colitis and analysis
was performed as previously described (11). At the time
of DSS or TNBS treatment (day 0), we administrated an
isotype control (IgG; R&D Systems, Minneapolis, MN, USA);
three different α-TREM-1 (4 or 20 µg/mouse based on a
previous study) (7); MAB1187 (R&D Systems) for experiments
in C57BL/6 mice (Figure 1); AF1187 (R&D Systems) for all
experiments, except those in Figure 2; or sc-19312 (Santa Cruz
Biotechnology, Dallas, TX, USA) for the indicated experiments
in BALB/c mice in Figure 2. All experiments using animals
were approved by the Institutional Animal Care and Use
Committee of Yonsei University Severance Hospital, Seoul,
Korea (Approval No: 2014-0299).
The detailed methods for disease activity index (DAI)
evaluation, histological analysis and immunohistochemistry,
depletion or transfer experiments of microbiota, and
metagenome analysis of microbiota are described in
Supporting Information.
Cell Culture, Treatment, and Transfection
Cells were maintained at 37◦C in RPMI1640 supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Life
Technologies, Gaithersburg, MD, USA) and 1% antibiotics in
a humidified atmosphere of 5% CO2. RAW264.7 macrophage
cells (Korean Cell Line Bank, Seoul, Korea), THP-1 cells, and
HL-60 cells (ATCC, Manassas, VA, USA) were used. Cells
were stimulated with IgG or α-TREM-1 at 0.4–0.8µg/mL,
with or without TLR ligands, including LPS (Sigma-Aldrich,
St Louis, MO, USA), flagellin (FLA-ST; InvivoGen, San Diego,
CA, USA), Pam3CSK4 (PAM3; InvivoGen), peptidoglycan
(PGN-BS; InvivoGen), muramyl dipeptide (MDP; InvivoGen),
and Salmonella enterica serovar typhimurium expressing green
fluorescent protein (GFP; ATCC14028GFP). S. typhimurium
expressing GFP was inoculated into 10mL of Luria-Bertani broth
at 37◦C, shaken at 250 rpm overnight, and then sub cultured into
50mL of LB broth, until mid-logarithmic growth was reached
(OD600: 0.5) as previously described (12). S. typhimurium was
then diluted in antibiotic-free medium.
Knockdown of the Trem1 gene was achieved through a 12-h
transfection of siRNA or non-targeting control siRNA (40µM;
AccuTarget, Bioneer, Daejeon, South Korea) into RAW264.7
cells using Lipofectamine 2000 (Life Technologies). To assess
the inflammatory response, treatment was performed 24 h
after transfection. Transfection experiments were performed
in duplicate on three independent occasions and the results
were averaged.
The detailed methods of bone marrow–derived
neutrophil and macrophage preparation are described in
the Supporting Information.
Phagolysosomal Acidification, Autophagy,
and Neutrophil Extracellular Trap Assay
Macrophages and neutrophils were cultured on poly-L-lysine-
coated confocal dishes and incubated with LPS (200 ng/mL)
or α-TREM-1 (0.8µg/mL) for 2 or 3 h, respectively. For the
phagolysosomal acidification assay, live cells were treated with
100 nM LysoTracker Red DND-99 (Thermo Fisher Scientific)
for 30min, washed with PBS, and stained with Hoechst 33342
(8 nmol/L, Thermo Fisher Scientific). For autophagosome
evaluation, cells were permeabilized with 0.1% Triton X-100
for 10min, washed with PBS, and incubated with an anti-
LC3B antibody (1:2,000; Abcam, Cambridge, UK) overnight.
An Alexa488-conjugated rabbit anti-mouse secondary antibody
(1:500, Thermo Fisher Scientific) was then added for 30min,
after which cells were fixed in 4% paraformaldehyde and stained
with DAPI or Hoechst 33342. For the neutrophil extracellular
trap assay, neutrophils were treated with 5 µM SYTOX orange
(Thermo Fisher Scientific) for 30min. All cells were visualized
using a fluorescence microscopy (Olympus BX41) or Carl Zeiss
LSM 700 laser-scanning microscope (Oberkochen, Germany). At
least 100 cells were counted in 10 high-powered fields.
The detailed methods of culture, knockdown, transfection,
neutrophil isolation, flow cytometric analysis, reactive
oxygen species measurement, RT-PCR, Western blotting,
wound healing assay, and immunostaining are described in
Supporting Information. Supplementary Table 1 summarizes
the patient characteristics. qPCR primers are listed in
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FIGURE 1 | α-TREM-1 prevents colitis and modulates the microbiota in mice. (A–F) Systemic administration of α-TREM-1 in DSS-treated mice. DSS was supplied in
drinking water and IgG or α-TREM-1 was intraperitoneally injected (4 or 20 µg/mouse) into BALB/c mice. (G–N) The antibiotic (Abx) cocktail was supplied in drinking
water 6 days before DSS administration (day 0) and IgG or α-TREM-1 (arrow: 20 µg/mouse) was intraperitoneally injected into BALB/c mice on day 0 (n = 8/groups).
(A,G) Experimental design. (B,H) Body weight change. (C,I) Disease activity index. (D,J) Representative sections of periodic acid-Schiff stain. Scale bar, 100µm.
(E,K) Histological score. (F) PAS stain intensity. (L) Goblet cell score. (M) Bacterial load. Bacterial load in colon was assessed by 16S rRNA gene amplification. (N)
Microbiota profiles (phylum level) in colonic tissues. Data are expressed as means ± S.E.M. (n = 4–8/groups). Statistical significance was assessed using one-way
ANOVA followed by Tukey post-test. *P < 0.05, **P < 0.01, ***P < 0.005 (or vs. DSS+IgG). α-T, treated with α-TREM-1; IgG, treated with control antibody; Water,
supplied with normal drinking water.
Supplementary Table 2. This study was approved by the
Institutional Review Board of Severance Hospital, Yonsei
University (approval number 4-2012-0302). All patients and
controls provided written informed consent and all methods
were performed in accordance with the relevant guidelines
and regulations.
Statistical Analysis
Prism 5.0 software (GraphPad Inc., San Diego, CA, USA) was
used for statistical analyses. A two-tailed Student’s t-test was used
to compare two datasets and analysis of variance (ANOVA) was
used for multiple comparisons. Significance was accepted at P <
0.05. Results are expressed as mean± S.E.M.
RESULTS
Intrarectal and Intraperitoneal
Administration of α-TREM-1 Protects Mice
From Colitis
We examined the effect of TREM-1 agonism by direct
intrarectal administration of α-TREM-1 agonist at the
time of TNBS treatment (day 0) into C57BL/6 mice
(Supplementary Figure 1A). Unexpectedly, we found that
α-TREM-1 induced body weight recovery, lowered DAI values,
and attenuated colon length shortening in a dose-dependent
manner (Supplementary Figures 1B–D). α-TREM-1 alleviated
histopathological changes (Supplementary Figures 1E–G),
suggesting that α-TREM-1 can directly impact mucosal
immunity through rectal administration. The TNBS-induced
colitis model that haptenates to the host immune system in the
intestine has been considered as a Th1-mediated CD-like colitis
model, and the DSS-induced colitis model that causes massive
colonic barrier loss has been considered a model of UC-like
disease (13, 14). To test whether α-TREM-1 had systemic effects,
we intraperitoneally administered α-TREM-1 at the time of
DSS treatment (day 0) to mice (Figure 1A). Like intrarectal
administration, α-TREM-1 dose-dependently attenuated
colitis (Figures 1B,C, Supplementary Figure 2A). Histological
evaluation of colons from α-TREM-1-treated mice revealed a
markedly decreased inflammation score (Figures 1D–F) and
showed near complete goblet cell restoration (Figures 1D,F).
To ensure these results were TREM-1 specific, we used three
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FIGURE 2 | TLR4 signaling is required for the anticolitic effects of α-TREM-1. Wild-type (WT) and Tlr4-knockout (Tlr4−/−) BALB/c mice were subjected to a colitis and
healing model with 3.5% DSS treatment for 7 days and normal drinking water for 2 days (n = 7/groups). The arrow indicates the point at which IgG- or α-TREM-1
(α-T) was administered (20 µg/mouse). (A) Experimental design. (B) Body weight change. (C) Disease activity index. (D) Representative sections of PAS stain. Scale
bar, 100µm. (E) Histological score. (F) Goblet cell score. (G) Total number of bacterial OTUs (left), richness predicted by the Chao1 index (middle), and diversity by the
Shannon index (right) in the colon. (H) Microbiota profiles in the colon at the phylum level. Statistical significance was assessed using one-way ANOVA followed by
Tukey post-test. *P < 0.05, **P < 0.01, ***P < 0.005. PBS administered phosphate-buffered saline; Water, supplied with normal drinking water.
different α-TREM-1 agonists with different epitopes (described
in the Methods section). The anti-colitic effects of α-TREM-
1 were not affected by the type of antibody. These results
confirmed that α-TREM-1 specifically activated TREM-1
signaling and induced anticolitic effects through intrarectal and
intraperitoneal administration, suggesting the involvement of
systemic modulators, such as neutrophils and macrophages, in
addition to mucosal immunity.
α-TREM-1 Promotes Bacterial Clearance
and Modulates Microbiota in Colitis
To further examine the involvement of bacterial modulation of
the anticolitic effects of α-TREM-1, we depleted endogenous
intestinal bacteria with broad-spectrum antibiotic (Abx)
treatment (Supplementary Figure 3A) and intraperitoneally
administered IgG or α-TREM-1 at the time of DSS treatment
(Figure 2G). Here, we used BALB/c mice to investigate the
effects of the mouse genetic background. Like α-TREM-1
treatment, Abx treatment alleviated colitis (Figures 1H–L,
Supplementary Figure 3B) in DSS-treated mice. Notably,
α-TREM-1 yielded stronger anticolitic effects when co-
administered with antibiotics. Next, we investigated bacterial
burden in colonic tissues. Bacterial load was significantly
reduced in the DSS+α-TREM-1, DSS+Abx+α-TREM-1,
and DSS+Abx groups compared to the DSS+IgG group
(Figure 1M). Correspondingly, we found that α-TREM-1 also
reduced colonic bacterial load in mice with TNBS-induced colitis
(Supplementary Figure 1H).
We evaluated changes in fecal and colonic microbiota
using 16S pyrosequencing. Feces from the Abx-treated
group showed compositional shifts to Bacteroidetes
(Supplementary Figures 3C,D), which is supposed to be due to
Abx treatment. Colon samples from α-TREM-1- and Abx-treated
mice revealed a different taxa composition compared to those
of IgG-treated mice, with a drastic decrease in Proteobacteria
and an increase in Firmicutes in DSS-treated mice (Figure 1N,
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Supplementary Figure 3E). Similar results were found in the
TNBS-treated mice (Supplementary Figures 1I–L), although
Bacteroidetes displayed slightly different profiles between the
DSS and TNBS models. These results indicate that α-TREM-1-
mediated attenuation of colitis was associated with restricted
dissemination of pathogenic bacteria and a change toward
non-pathogenic compositions in the early stage of inflammation.
TLR4 Signaling Is Required for Anticolitic
Effects of α-TREM-1
Because the interaction between TREM-1 and TLR4 is crucial for
antimicrobial and anti-inflammatory functions, we investigated
the therapeutic effects of α-TREM administration in Tlr4- and
Myd88-knockout (KO) BALB/c mice through intraperitoneal
administration of α-TREM-1 2 days after DSS treatment
(Figure 2A, Supplementary Figure 5A). As seen in C57BL/6
mice, α-TREM-1 markedly attenuated colitis in wild type
(WT) BALB/c mice. However, α-TREM-1 treatment did not
alleviate colitis in Tlr4- and Myd88-KO mice (Figures 2B,C,
Supplementary Figures 4, 5). It was also unable to restore goblet
cells or improve histopathology in Tlr4-KO mice (Figures 2D,E)
and Myd88-KO mice (Supplementary Figure 5E). Additionally,
α-TREM-1-treated WT mice showed an increase in microbiota
diversity (Figure 2G, Supplementary Figure 4C). This
therapeutic model also showed a shift to Firmicutes in the
colonic tissue of α-TREM-1-treated WT mice, but significant
suppression of pathogenic Proteobacteria in DSS-treated
mice. This shift was absent in Tlr4- or Myd88-KO mice
(Figure 2H, Supplementary Figures 4D, 5F). α-TREM-1
treatment drastically increased expression levels of genes related
to bacterial clearance, such as Inos and Il1b, in the affected colon
ofWTmice compared to untreated mice. In addition, α-TREM-1
treatment resulted in a trend toward increased Il22 expression
(Supplementary Figure 4E). On the other hand, α-TREM-1
treatment did not affect Inos, Il1b, or Il22 expression in Tlr4-KO
mice. These results suggest that TLR4 signaling is associated
with the anticolitic effects of α-TREM-1 through the control of
gut microbiota.
To assess whether the nullified anticolitic effects of α-
TREM-1 in Tlr4-KO mice were due to gut microbiota
changes, we cohoused Tlr4-KO mice with WT mice that
were intraperitoneally treated with IgG- and α-TREM-1
6 times weekly to facilitate the exchange of microbiota
(Supplementary Figure 6A). Body weight recovered until
day 8 of DSS-treatment in α-TREM-1-treated mice, but
this effect disappeared at the end of the observation
period (Supplementary Figure 6B). Cohousing did not
improve DAI values, colon length, or histopathology
(Supplementary Figures 6C–G), and there was no induction
of IL-22-producing neutrophils or M2 macrophages in α-
TREM-1-treated mice (Supplementary Figures 6H,I). Next, we
performed daily oral fecal microbiota transplantation (FMT) to
DSS-treated mice for 9 days using feces obtained from cohousing
experiments (Figure 3A). FMT from IgG- and α-TREM-1-
treated mice alleviated body weight loss until day 8, but Tlr4-KO
mice rapidly became debilitated when FMT ceased (Figure 3B).
FIGURE 3 | Fecal microbiota transplantation. WT mice were intraperitoneally
treated with IgG- and α-TREM-1 6 times weekly and mouse feces were
collected daily. Tlr4-knockout mice were orally administered fecal microbiota
(FM) from the treated mice daily for 8 days after 3% DSS treatment, and DSS
was changed with drinking water for 2 days until the endpoint of the
experiment (n = 5/groups). The arrow indicates the point at which FM was
administered. (A) Experimental design. (B) Body weight change. (C) Disease
activity index. (D) Representative sections of PAS stain. Scale bar, 100µm. (E)
Histological score. (F) Goblet cell score. Statistical significance was assessed
using one-way ANOVA followed by Tukey post-test. *P < 0.05, **P < 0.01,
***P < 0.005. PBS administered phosphate-buffered saline; Water, supplied
with normal drinking water.
In addition, DAI values and colon length were similar between
all DSS-treated groups (Figure 3C, Supplementary Figure 7A),
despite a slight restoration of goblet cells and histology in the
colons of α-TREM-1-treated Tlr4-KO mice (Figures 3D–F).
FMT of WT mice treated with α-TREM-1 to DSS-treated
Myd88-KO mice yielded similar observations to that of Tlr4-KO
mice (Supplementary Figures 7B–H). Overall, fecal microbiota
appeared to have a temporary effect on α-TREM-1, suggesting
that other basic host elements are critical in the anti-colitic effect
of α-TREM-1.
Anticolitic Effects of α-TREM-1 Are
Mediated by Neutrophils and Macrophages
TREM-1 is primarily expressed in cells of myeloid origin, such
as neutrophils and macrophages (4). Therefore, we depleted
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neutrophils or macrophages with Ly6G antibody or clodronate
liposome treatment, respectively, and assessed whether α-TREM-
1-treated mice were still susceptible to DSS-induced colitis
(Figure 4A, Supplementary Figure 8D). Colitis worsened in
Ly6G- and clodronate-treated mice (Figures 4B–D). Moreover,
histopathological scores and goblet cells were significantly
different between α-TREM-1-treated mice treated with vehicle
and those treated with Ly6G (Figures 4C–E), demonstrating that
neutrophils and macrophages were required for the protective
effect of α-TREM-1. However, clodronate treatment was not
sufficient to block α-TREM-1 effects and induce IL-22-producing
CD177+ neutrophils (Figure 4F). Of note, the increase in
iNos expression induced by α-TREM-1 was abolished by Ly6G
treatment (Figure 4G). This suggests that the presence of
macrophages was insufficient to mediate the anticolitic effects of
α-TREM-1, but the presence of neutrophils was critical.
α-TREM-1 Promotes Bacterial Clearance
by Modulating Neutrophil and Macrophage
Function
Since IBD is associated with many genetic variants that
affect bacterial clearance, such as NOD2, and autophagy,
such as ATG16L1 (15), we assumed that increased bacterial
clearance after α-TREM-1 treatment resulted from increased
autophagy. To assess the effect of α-TREM-1 on bacterial
clearance in macrophages, we infected RAW264.7 cells with
live GFP-expressing S. typhimurium, an invasive intestinal
pathogen. Intracellular bacteria were detected as GFP (live)
and Hoechst (dead) signals as previously described (15). α-
TREM-1 treatment significantly increased the percentage of dead
bacteria (Figures 5A,B, Supplementary Figures 9A–C). Since S.
typhimurium lipopolysaccharide (LPS), a TLR4 ligand, induces
autophagy in RAW264.7 cells, we stained lysosomes and LC3B
using a lysotracker probe (or anti-LAMP-1) and an anti-LC3B
antibody, respectively. We observed significantly increased
GFP signal localized to lysosomes in α-TREM-1-treated
cells (Figure 5B, Supplementary Figures 9B,C), indicating
increased fusion of S. typhimurium-containing phagosomes
with lysosomes and confirming decreased bacterial survival
after α-TREM-1 treatment. We found an increase in LC3-II
level and endogenous processing of lysosomes in α-TREM-
1-treated cells using immunostaining and western blotting,
respectively (Supplementary Figures 9D–F). Short interfering
RNA (siRNA) was used to knock down Trem1. α-TREM-1-
treated RAW264.7 cells showed increased lysotracker levels,
but not in Trem1-knockdown cells (Figure 5C). Collectively,
these results show that α-TREM-1 further activates phagocytosis
by macrophages.
Induction of CD177+ Neutrophils by
α-TREM-1 Promotes Wound Healing and
Colitis
Recently, it was demonstrated that CD177+ neutrophils are
functionally activated and negatively regulate IBD through IL-
22 production (16). In agreement, we found that CD177 and
IL-22 were markedly increased in the colons of α-TREM-1-
treated mice (Figure 6A, Supplementary Figures 2B,C). After
co-stimulation with LPS and α-TREM-1, we also observed an
increase in CD177 and IL-22 expression in bone marrow-
derived neutrophils (BMDNs) from WT mice as mouse primary
neutrophil cells and in HL-60 cells as human neutrophil
cells, but not in BMDNs from Tlr4-KO mice (Figure 6B,
Supplementary Figure 10A) or in TREM1-knockdown HL-60
cells (Figure 6C, Supplementary Figure 10B). An additional
pathogen-elimination mechanism was found for neutrophils in
which they form neutrophil extracellular traps (NETs) (17).
α-TREM-1-treated control HL-60 cells dramatically increased
NET formation after LPS treatment, which was inhibited
by TREM1 knockdown (Figure 6D). Furthermore, α-TREM-
1 treatment increased autophagy in HL-60 cells and BMDNs
(Supplementary Figures 10C,D). To confirm that α-TREM-
1 promotes CD177+ neutrophil differentiation in IBD, we
examined the CD177+IL-22+ population after α-TREM-1
treatment of neutrophils from healthy controls and IBD patients,
with or without LPS and IL-23. CD177+IL-22+ populations in
neutrophils were significantly increased by α-TREM-1 treatment
in both healthy controls and IBD patients (Figure 6E). Likewise,
α-TREM-1 increased ROS production (Figure 6F) and LPS-
induced CD177, IL22, and TNFA expression in neutrophils from
IBD patients (Supplementary Figure 10E).
Next, we evaluated the role of α-TREM-1-treated neutrophils
in intestinal barrier regulation, investigating whether increased
wound healing occurs through IL-22 released by CD177+
neutrophils. Scraped colonic epithelial HT-29 cells were cultured
in conditioned media from HL-60 cells treated with IgG or
α-TREM-1 and various TLR ligands. HT-29 cells grown in
media containing α-TREM-1-treated HL-60 cells and LPS+IL-
23 showed greater wound closure than those grown in media
containing Ig-G-treated HL-60 cells with LPS+IL-23 or LPS
(Figure 6G, Supplementary Figure 10F). Like HL-60 cells, α-
TREM-1-treated neutrophils from IBD patients promoted
wound closure (Figure 6H, Supplementary Figure 10H).
We intraperitoneally injected α-TREM-1 (Figure 7A)
and investigated changes in IECs and gene expression in
colon tissues. α-TREM-1 administration markedly increased
goblet cell numbers (Figure 7B) and expression of genes
related to CD177+ neutrophils, macrophages, phagocytosis,
and Tlr4 (Figures 7C,D, Supplementary Figures 11A–D).
M2 macrophage marker levels also increased in LPMCs
after α-TREM-1 treatment (Figure 7E). To further confirm
the role of CD177+ neutrophils in the anticolitic effects
of α-TREM-1, we identified the differentiation of CD177+
BMDNs by α-TREM-1. We then prepared CD177+
and CD177− BMDNs 1 day after α-TREM-1 treatment
(Supplementary Figure 11E) and performed neutrophil
transfer into mice on day 2 of DSS treatment (Figure 7F,
Supplementary Figure 11E). CD177+ BMDN transfer
markedly attenuated colitis and restored goblet cell numbers
(Figures 7G–K, Supplementary Figure 11F). Flow cytometric
analysis indicated that transferred CD177+ neutrophils migrated
to the colon (Supplementary Figure 11G). These results
highlight the importance of the TREM-1 pathway in CD177+
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FIGURE 4 | Neutrophils and macrophages mediate α-TREM-1-induced anti-colitic effects. BALB/c mice were intraperitoneally given an anti-Gr1 antibody (Ly6G) twice
to deplete neutrophils or clodronate (Clo) twice to deplete macrophages. Both these groups were then injected once with IgG or α-TREM-1 (20 µg/mouse) at day 2.
After DSS treatment for 8 days, DSS was exchanged for drinking water for 2 days (n = 4–6/groups). (A) Experimental design. (B) Disease activity index. (C)
Representative sections of a periodic acid-Schiff stain. Scale bar, 100µm. (D) Histological score. (E) Densitometry analysis of periodic acid-Schiff stain. (F) Flow
cytometric analysis of macrophages and CD177+ neutrophils in lamina propria mononuclear cells. (G) qRT-PCR analysis of Inos expression profiles in colons. Each
data represents the mean of duplicate real-time RT-PCR (n = 3–4). Data are expressed as means ± S.E.M. Statistical significance was assessed using one-way
ANOVA followed by Tukey post-test (B,G) or Student t-test (D,E). *P < 0.05, **P < 0.01, ***P < 0.005. α-T, treated with α-TREM-1; IgG, treated with control
antibody; Water, supplied with normal drinking water.
neutrophils, which leads to pathogen clearance and protection of
the intestinal barrier in colitis.
DISCUSSION
IBD features neutrophil infiltration of the intestinal mucosa and
repeated epithelial injury (1). However, neutrophils play essential
roles in the innate immune response, resolution of inflammation,
and healing processes in colitis (16, 18, 19). Indeed, a variety of
defects in neutrophil function have been described in CD patients
(20, 21). They play a critical bactericidal role as the first line using
ROS/RNS intermediates, antimicrobial peptides, or NETs (22).
In addition, the limited antimicrobial capacity of macrophages
can be supplemented through the acquisition of neutrophilic
microbicidal molecules or directly by neutrophil products,
including released granule molecules (19, 23). Neutrophils
from TREM-1-deficient mice have reduced ROS production,
poor neutrophil recruitment, impaired pathogen clearance, and
increased bacterial translocation and tissue damage in the
intestine (8). In addition, CD177+ neutrophils have bactericidal
activity and produce high levels of ROS, NET, IL-22, and
antimicrobial peptides, and low levels of proinflammatory
cytokines (16). These cells have an indispensable protective role
in IBD (16), which is consistent with our data. Interestingly,
CD177 is also an endogenous TREM-1 ligand (24), and CD177-
deficiency leads to neutrophil death (25). Neutrophils can
also enhance intestinal mucosal wound healing and barrier
function through interactions with IECs (26). We showed
that α-TREM-1 induced CD177+ neutrophils in the blood of
IBD patients and healthy controls, and that α-TREM-1-driven
CD177+ neutrophils ameliorate mouse colitis. These results
suggest that CD177+ neutrophils limit inflammation through
bactericidal activity and promote wound repair induced by IL-
22 production, although our neutrophil depletion model can also
induce opsonization and phagocytosis of targeted cells (27).
Pathogens stimulate pattern recognition receptors (PRR)
via their pathogen-associated or damage-associated molecular
patterns and induce proinflammatory mediators including TNF
and IL-1β through NF-κB activation. This situation may mediate
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FIGURE 5 | α-TREM-1 promotes bacterial clearance through increased macrophage autophagy. (A,B) RAW264.7 cells were pre-treated with IgG or α-TREM-1 and
infected with S. typhimurium expressing green-fluorescent protein (A, multiplicity of infection MOI = 10; B, MOI = 100) for 1 h. (A) Representative images of S.
typhimurium-GFP-infected macrophages and quantification of the total number of bacteria per macrophage (right). Scale bar, 20µm. (B) Representative images of
lysotracker (Lyso)-stained macrophages and the percentage of S. typhimurium-GFP in autophagic degradation (GFP co-localization with lysosomes). GFP+Lyso+
area was calculated by subtracting pure green GFP signal from total GFP signal. Scale bar, 20µm. Hoechst (Hoec) staining of nuclei. (C) Representative images of
lysotracker-stained macrophages. Scale bar, 40µm. RAW264.7 cells transfected with scrambled (SCR) or TREM1-specific (siT) siRNA were stimulated with LPS for
4 h after pre-treatment with α-TREM-1. Data are expressed as means ± S.E.M. of at least three independent experiments. Statistical significance was assessed using
Student t-test. *P < 0.05, ***P < 0.005. α-T, treated with α-TREM-1; DIC, differential interference contrast; IgG, treated with control antibody; Sal, infected with S.
typhimurium-GFP; Veh, treated with vehicle.
inflammation and help maintain gut barrier functions as a
host defense mechanism (6, 15, 28). In contrast to studies
on the deleterious roles of TREM-1 which had focused on
blocking signaling (10), a large body of evidence suggests a
beneficial role of TREM-1 agonists in bacterial clearance and
infection resolution (7, 8, 29). Likewise, we found that co-
administration of antibiotics with α-TREM-1 further reduced
pathogenic bacterial load and markedly ameliorated colitis by
significantly decreasing the proportion of Proteobacteria, which
are Gram-negative bacteria that can induce colitis. Cohousing
and FMT between α-TREM-1-treated mice and Tlr4-KO mice
temporarily suppressed gut inflammation, suggesting that host
immune response through TLR4 signaling is required for
sustained effects. TLRs lead to important bactericidal activity
through ROS generation (6), cytokine production, and IL-22
production in the colon (30). Consistently, Tlr4- andMyd88-KO
mice are more susceptible to infection and colitis than WT
mice due to increased bacterial translocation (31, 32) and
decreased AMP expression (31). Likewise, we observed an
increase in bacterial invasion and a decrease in the anticolitic
effect of α-TREM-1 in Tlr4- and Myd88-KO mice, as well
as high expression of inducible nitric oxide synthase (iNOS)
and neutrophil ROS production in the colons of α-TREM-1-
treated mice. Defects involving microbial sensing and bacterial
handling pathways, including ROS production and antimicrobial
autophagy, are also associated with enhanced risk of IBD
(15). TREM-1 also cooperates with other PRRs and has
synergistic effects on proinflammatory cytokine production (33);
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FIGURE 6 | α-TREM-1 facilitates the cooperation of CD177+ neutrophils with intestinal epithelial cells and macrophages. (A) Representative images of CD177
immunostaining in colon tissues. Scale bar, 20µm. (B) Cd177 expression in mouse bone marrow-derived neutrophils (BMDNs) from wild-type and Tlr4-KO mice.
BMDNs and HL-60 cells pre-treated with α-TREM-1 (0.8µg/mL) were treated with lipopolysaccharide (LPS, 200 ng/mL) for 4 h for qRT-PCR analysis. Each data
represents the mean of duplicate real-time RT-PCR (n = 3). (C,D) HL-60 cells transfected with scrambled (SCR) or TREM1-specific (siT) siRNA were pre-treated with
α-TREM-1 and stimulated with LPS for 1 h. (C) CD177 expression in human neutrophils treated with α-TREM-1. Each data represents the mean of duplicate real-time
RT-PCR (n = 3). (D) Representative images from the neutrophil extracellular trap assay. Data are from one experiment representative of three independent
experiments. Scale bar, 40µm. (E) Modulation of CD177+ IL-22+ neutrophils in the blood of inflammatory bowel disease (IBD) patients by α-TREM-1. Flow cytometric
analysis was performed to evaluate the CD177+ IL-22+ cells in neutrophil populations extracted from ulcerative colitis (UC) and Crohn’s disease (CD) patients and
healthy subjects (n = 5). Numbers indicate CD177+ IL-22+ cell frequencies among neutrophils. (F) Reactive oxygen species (ROS) production in neutrophils of IBD
patients. (G,H) Wound healing assay. HT-29 cells were cultured in conditioned media from HL-60 cells (G) or blood neutrophils of UC patients (H) after α-TREM-1
treatment and wound healing assays were performed. Data represent the average of four independent experiments. Statistical significance was assessed using
one-way ANOVA followed by Tukey post-test. * and #P < 0.05, **P < 0.01, *** and ###P < 0.005 vs. vehicle (Veh). Data are expressed as means ± S.E.M. (n =
4–5). α-T, treated with α-TREM-, treated with control antibody; Water, supplied with normal drinking water.
we have obtained corresponding results in vitro. However, our
data showed that TLR4 signaling mainly mediates the anti-
inflammatory effects of α-TREM-1. Intriguingly, a NOD2 ligand
(MDP) and peptidoglycan (PGN) did not increase TREM-
1 expression and LPS co-stimulation with a TLR1/2 agonist
(PAM3CSK4) showed suppressive effects on iNOS, COX-2, and
TREM-1 expression (Supplementary Figure 9G). Furthermore,
suppression of TREM-1 by other TLR ligands such as FLG or
PAM3 may be responsible for the suppression of wound healing
(Supplementary Figure 10G). These data indicate that TREM-
1 may selectively sense microbiota and respond accordingly,
and thus may explain how NOD2 mutation influences bacterial
handling in CD (15). Taken together, our data suggest that TLR4
signaling mediates the anti-inflammatory effects of α-TREM-1,
and is an important TLR for pathogen control in IBD (34).
The innate immune response is pivotal as a primary defense
against intestinal microbiota and provides initial resistance
to invading pathogens (34). In this context, we showed that
bacterial clearance with antibiotic pre-treatment alleviated colitis,
suggesting that bacterial handling at the early stage is important
for control of gut inflammation and microbiota modulation. We
postulate that α-TREM-1 can control pathogens at the early
stage of gut inflammation. Here, we also showed that α-TREM-
1 enhanced phagocytosis and autophagy in macrophages and
neutrophils, as reported in previous studies (35, 36).Macrophagic
engulfment of apoptotic neutrophils is required for wound
healing and ROS production (15, 37). Moreover, autophagy is
required for the NETosis pathway in neutrophils (38), suggesting
that autophagy is important for preventing bacterial spread.
Recently, autophagy induction was suggested as a therapeutic
strategy for IBD (39, 40). Contradictory to our results, a few
studies using Trem1-KOmice reported the following: (1) TREM-
1 deficiency can attenuate disease severity without affecting
parasitic and viral infections; (2) TREM-1 deletion restores
impaired autophagy (41); and (3) TREM-1 inhibition using LR12
peptide attenuates experimental colitis by restoring impaired
autophagy (42). However, we cannot fully exclude the possibility
of different mechanisms between TREM-1 deficiency and α-
TREM-1. For example, we found that Trem1-KO mice had
higher DAI values in normal condition without colitis (42).
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FIGURE 7 | α-TREM-1-induced CD177+ neutrophils confer anticolitic effects. (A–E) α-TREM-1 was intraperitoneally injected to C57BL/6 mice and the next day,
colons were isolated for analysis. (A) Experimental diagram. The arrow indicates the point at which IgG- or α-TREM-1 was administered (20 µg/mouse). (B) Goblet
cell score. (C,D) Expression of Cd177+ neutrophil- (C: Cd177, Il22, and Inos) and macrophage-specific (D: Mip2 and Il10rb2) genes in the colon. Each data
represents the mean of duplicate real-time RT-PCR (n = 4). (E) Flow cytometric analysis of M2 (CD206+) in macrophage (F4/80+Cd11b+) populations among lamina
propria mononuclear cells. (F–J) Bone marrow-derived neutrophils were isolated, treated with IgG or α-TREM-1 for 24 h, and sorted by FACS into CD177+ and
CD177−, which were then intraperitoneally injected (1 × 106 cells, arrow) into recipient mice 2 days after DSS treatment. (F) Experimental design for neutrophil
transfer. (G) Body weight change. (H) Disease activity index. (I) Representative sections of periodic acid-Schiff staining. Scale bar, 200µm. (J) Histological score. (K)
Goblet cell score. (L) Schematic representation of anticolitic effects of α-TREM-1. Data are expressed as means ± S.E.M. (n = 4/groups). α-T, treated with α-TREM-1;
AMP, antimicrobial peptides; IgG, treated with control antibody; HBSS, injected with Hank’s balanced salt solution; IEC, intestinal epithelial cell; IgG, treated with
control antibody; M8, macrophage; Neu, neutrophil; RNS, reactive nitrogen species; ROS, reactive oxygen species. Statistical significance was assessed using
Student t-test (B–D) or one-way ANOVA followed by Tukey post-test (G,H,J,K). *P < 0.05, **P < 0.01, ***P < 0.005.
These contradictory results should be interpreted cautiously
because agonists and antagonists may have different effects due
to subtly different modes of action. Consistently, a recent study
that TREM-1 loss exacerbates colitis in several mouse models
solidifies our results (43).
As depicted in Figure 7L, α-TREM-1 modulated the
bacterial clearance activity of macrophages and neutrophils
and promoted the differentiation of neutrophils into
CD177+ cells, leading to enhanced protection against both
microbes and tissue damage. We speculate that the intrinsic
modulatory mechanism of anti-TREM-1 antibody, including
the alteration of macrophage function, is at least in part
related with CD177+ neutrophils, although the mechanism
of the anticolitic effect of α-TREM-1 is probably multi-
factorial. Additionally, we can postulate that the upregulated
TREM-1 levels in IBD may be due to impaired neutrophil
function (19, 44), neutrophil recruitment (36, 45), or TLR
signaling (46), but this requires further elucidation of the
mechanisms by which α-TREM-1 alleviates colitis as well
as its role in IBD pathogenesis. Moreover, we need further
information on whether the function and differentiation of
CD177+ neutrophils can be affected by genetic variations
in patients with IBD and their effects on the function of
macrophages, such as autophagic capability, ROS production,
and M2 polarization.
This is the first study to demonstrate that stimulation of
TREM-1 signaling using α-TREM-1 is effective at attenuating
colitis. We showed that α-TREM-1 augmented bactericidal
activity via reciprocal interactions between TLR4 and TREM-
1, and improved wound healing via the interaction of
macrophages, neutrophils, and the intestinal epithelial barrier.
Furthermore, we identified α-TREM-1 as a candidate regulator
of CD177+ neutrophils, which are pivotal players in achieving
a balance between microbe control and tissue repair in the
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gut. Although immune-suppressive therapies such as anti-
TNF agents are effective at ameliorating symptoms in some
IBD patients, continued treatment increases susceptibility to
infection (47). Further insights into the role of α-TREM-1
in IBD pathogenesis may provide a new therapeutic target
for IBD.
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